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Abstract: Metabolic system modeling for use in glycaemic control is increasing in importance. Few 
models are clinically validated for both fit and prediction ability. For such models, this research introduces 
a new form of pharmaco-dynamic (PD) surface comparison for model validation. These 3D surfaces are 
developed for 3 validated models, including the well-known Minimal Model, and fit to clinical data. The 
approach is clearly highlights differences in modeling methods, dynamics utilized and physiological 
assumptions that may not appear as clearly in other validation approaches. The deficiencies of the Minimal 
Model in comparison to more physiologically representative models are illustrated in this context. 
 
1. INTRODUCTION 
Type 1 and Type 2 diabetes are epidemic with significant 
economic cost driven by the inability of individuals, and their 
clinicians, to adequately control blood glucose levels. Hence, 
the rate of costly chronic complications is rising. Critical care 
studies (van den Berghe et al (2001); Krinsley (2002)) have 
shown tight glycaemic control can significantly reduce 
mortality and cost (Krinsley, 2006). However, achieving it 
has proven difficult, even though initial results show tighter 
control is better (Chase et al, 2007; Egi et al, 2007).  
The potential of models for managing glycaemic levels in any 
insulin resistant cohort is thus of growing import. However, 
relatively few models have been clinically validated. For 
most, the primary form of validation has been simple fitting 
of the model to clinical data. Occasionally, more rigorous 
prediction validation is used. However, only a few clinically 
validated models can predict within clinically acceptable 
ranges (e.g. Wong et al, 2006; Lotz et al, 2006; Arleth et al, 
2000; Hovorka et al, 2004).  
This paper presents a new form of model validation, by 
examining the steady state pharmaco-dynamic (PD) surfaces, 
including underlying pharmaco-kinetics (PK). A 3D surface 
of plasma insulin (x), plasma glucose (y) and resulting rate of 
change in endogenous glucose balance (z) is compared to 77 
sets of glycaemic clamp data (Arleth et al, 2000), creating a 
new form of clinical model validation in the comparison.  
2. METHODS 
2.1  Models 
Three clinically validated models are used in this analysis: 
1. Non-linear PK/PD Model (ND) 
2. Minimal Model (MM) 
3. Receptor Model (RM) 
The ND model has been used in several critical care studies 
(e.g. Wong et al, 2006). The MM is well documented and 
used (Pacini et al, 1986). The RM model was developed for a 
Type 1 diabetes decision support system (Arleth et al, 2000).  
The dynamic models (MM, ND) share the same basic PD 
formulation and can be jointly defined (Lotz et al, 2006): 
 
where G(t) [mmol/L] is the total plasma glucose, Q(t) [mU/L] 
is interstitial insulin assumed equal to plasma insulin in this 
steady state analysis, P(t) [mmol/min] is exogenous 
carbohydrate appearance, Pend [mmol/min] represents 
endogenous glucose appearance in a glucose distribution 
volume VG. Patient endogenous glucose clearance and insulin 
sensitivity are pG [1/min] and SI [L/(mU.min)]. Michaelis-
Menten function αG [L/mU] captures saturation of plasma 
insulin disappearance and glucose uptake by insulin, and αG2 
[L/mmol] allows for the saturation of glucose-dependent 
glucose clearance.  
Clinical trials, fitting and prediction validation, and model 
details for the ND model can be found elsewhere (e.g. Wong 
et al, 2006; Hann et al, 2005). The Minimal Model (MM) is 
thus effectively the case where: Pend = αG2 = αG = 0, -pG*G is 
redefined as -pG*(G-GE), where GE is a basal glucose value 
not used in the ND model of Equation (1), but defined in the 
MM (e.g. Pacini et al, 1986), and SI is the ratio used in the 
original MM formulation for active insulin. 
In this steady state PD surface analysis, Q(t)  Qss and G(t) 
 Gss, and Ġ  Pss in Equation (1) represent the endogenous 
balance change for that input in the steady state. Hence, the 
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steady state ND and MM model pharmaco-dynamics can be 
obtained from versions of Equations (1). 
The receptor model (RM) is defined (Arleth et al, 2000): 
where all terms and values are as defined in Arleth et al, 
(2000). Note that this model is defined based on clinically 
observed gains/losses from the liver (Hepatic), and losses to 
the kidneys (Renal), insulin-dependent periphery (P14) and 
insulin-independent periphery (P13). Hence, this receptor 
based model is physiologically defined. Finally, Is is a 
saturated insulin effect for insulin-dependent uptake, and it 
should be noted that P13 is a saturable insulin independent 
uptake of glucose and P14 a saturable insulin dependent 
uptake. The other specific values are obtained by fitting to 77 
clinical studies.  
The net results of this model (EndoBal) creates the 3D PD 
surface used for this comparison. This surface must be 
mathematically defined for the MM and ND models. Note 
that the RM model was created by directly fitting to clinical 
data, and thus needs no further alteration or analysis. 
2.2  PD Surface Fitting and Error Metrics 
To fit the PD surface for the ND and MM cases, a grid search 
was used over physiological ranges of important variables. In 
this case, the values of αG2, αG, SI were allowed to vary with 
Pend, PG, and VG set to constants, as in Table 1. The 
physiological ranges for αG2, αG, SI are based on an extensive 
literature search, model validation study and sensitivity study 
(Hann et al, 2005), and are also shown in Table 1 for normal 
subjects, as the clinical studies utilised normal subjects. 
Table 1: Variable values used in ND and MM analyses 
 Value 
PG 0.006 min
-1
 
VG 13.3 L (for 70kg), VG = 0.19*Mass (kg) 
Pend 1.2 mmol/L/min               (0 for the MM case) 
SI 1.5e-3 – 3.5e-3 L/mU/min 
αG 1/20 – 1/80 L/mU             (0 for the MM case) 
αG2 1/5 – 1/20 L/mmol            (0 for the MM case) 
 
For each set of variables in the lower part of Table 1, Ġ = -Pss 
is calculated from the model at the (Qss, Gss) from each of the 
77 clamp studies, creating 77 sets of (Qss, Gss)Ġ = -Pss 
points for each combination of (αG2, αG, SI). Importantly, this 
approach assumes that the steady state glucose infusion in the 
clamp (Pss) is the negative of the glucose rate of change (Ġ) 
that would occur without it. Hence, these terms represent the 
same value, with Pss for the clamp infusion to maintain 
euglycaemia and Ġ for the equivalent endogenous balance 
change that would occur for the given glucose and insulin 
levels without it. The difference is in the sign with Pss 
positive and Ġ negative in this usage.  
Details on the clamp cohort (n = 77) are in Arleth et al (2000) 
but consist of a wide selection of euglycaemic and 
hyperglycaemic clamp studies in the literature. 
Overall, 11,424 variable sets (αG2, αG, SI) result in 77 error 
values (per set) in endogenous balance, summarised by:  
1. RMS Error (RMS) – this metric rewards solutions that 
minimise error over all studies. 
2. Absolute Mode of Error (AME) – most frequent 
absolute error, rewarding solutions with more errors 
near zero and allows more outliers to account for 
variation observed in clamp studies. 
3. Frequency of Error Near Zero (FNZ) – number of 
errors within +/-0.025 of 0.000 error value or ~5% of 
mean Ġ observed in the clinical studies. This metric 
rewards solutions that have greater concentrations 
within observed glycaemic clamp variability of 5%, 
regardless of the specific mode. 
Each error metric rewards different quality of fit. RMS 
minimises outliers, without accounting for outlying clinical 
results or variation. AME rewards solutions that maximise 
“inliers” but not to a specific value. FNZ rewards “inlier” 
solutions within clinically observed variability for glycaemic 
clamps, allowing outliers for study variability and error. The 
grid search results were analysed based on all three metrics, 
and compared to the RM results. Differences are then 
discussed in the context of the model dynamics. 
Note that the RM model of Equations (2)-(7) was created by 
direct fitting to this data, and needs no further alteration. 
3. RESULTS & DISCUSSION 
Results are presented for 2 basic model types from Equations 
(1)-(3). The MM model where there is no saturation (αG = αG2 
= 0), and the ND model with either 1 non-zero saturation 
(αG) term denoted ND1, or with both saturation terms (αG and 
αG2), which is denoted ND2.  
Figure 1 shows the histograms comparing the ND2 model 
when sorted by RMS and FNZ. FNZ and AME results were 
similar, so the latter is not shown. FNZ allows more outliers, 
but has greater numbers around zero. Qualitatively FNZ was 
used because the results were almost identical in the ND2 
case, and identical in the ND1 and MM cases. The use of 
FNZ may account slightly more for variation in methods and 
procedures in the clinical study than RMS.  
Figure 2 compares the errors for the ND1 and RM cases. As 
expected, the RM model is tighter having been fit to this 
clinical data in its derivation. The ND2 model error is more 
tightly distributed than ND1. Interestingly, the ND1 and ND2 
models had greater FNZ than the RM model, but slightly 
EndoBal = Hepatic – Renal – P13 – P14 (2) 
Hepatic = -0.46min
-1
 G – 1.475mmol/min/mU Is + 
1.259mmol/L/min;    Gmax=12.0 mmol/L 
(3) 
Renal = 0.004L/mmol/min G2 – 0.064min-1 G + 
0.278mmol/L/min 
(4) 
P13 = 0.56min
-1
 *G/(G + 1.5mmol/L) (5) 
P14 = 5.09mmol/L/min/mU G*Is /(G+5.0 mmol/L) (6) 
Is = I * 1/((I-0.083mU/L)
1.77
+ (0.539mU/L)
1.77
)
(1/1.77) 
(7) 
  
     
 
wider distributions. The MM is not shown due to its very 
wide distribution of errors. 
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Fig. 1: ND2 error histogram, RMS vs FNZ metrics 
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Fig. 2: ND1 and RM errors. Note ND1 results were identical 
for RMS and FNZ metrics. 
FNZ sorted error results are given in Table 2, with relatively 
tight ND1 and ND2 distributions, compared to the RM 
model. In contrast, the MM has very large error and outliers. 
Table2: Results (parameter values and errors). Best FNZ 
and RMS results are identical for the ND1, MM and RM 
Model Values 
ND1 αG = 1/48 L/mU, αG2 = 0 L/mmol,  
SI = 0.0016 L/mU/min 
RMS = 0.07; AME = -0.01, FNZ = 36 
ND2 
Best FNZ 
αG = 1/44 L/mU, αG2 =1/7 L/mmol,  
SI = 0.0029 L/mU/min 
RMS = 0.06; AME = -0.01, FNZ = 39 
ND2 
Best RMS 
αG = 1/50 L/mU, αG2 =1/5 L/mmol,  
SI = 0.0032 L/mU/min 
RMS = 0.05; AME = -0.00, FNZ = 38 
MM αG = αG2 = 0 L/mU &  L/mmol 
SI = 0.0015 L/mU/min 
RMS = 4.77; AME = -0.05, FNZ = 3 
RM RMS = 0.04; AME = -0.01, FNZ = 32 
ND1, ND2 and RM are similar, while the MM model is quite 
different. Sorting for best RMS or FNZ for ND2 has no 
effect, and optimal solutions were robust over the variables. 
However, small differences in error are more evident in 
waterfall plots of the insulin-endogenous balance plane.  
Figures 3-4 show these waterfalls for the MM. Outlying 
errors are clearly due to the linear nature of the MM model 
glucose-insulin dynamics in this plane. In these figures, lines 
of constant glucose increase in value from the top to bottom 
lines, with clinical data marked individually. The MM errors 
will be very large for the higher insulin level values in Figure 
3, resulting in the large RMS error of Table 2. 
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Fig. 3: MM waterfall with lines showing constant glucose at 
Gss = 4.0, 4.5, 5.0, 5.5 and 6.0 mmol/L.  Clinical Studies: 
Squares: Gss = 4-4.75 mmol/L, Circles: Gss = 4.75-5.25 
mmol/L and Triangles: Gss = 5.25-6.0 mmol/L.  
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Fig. 4: MM waterfall with lines showing constant glucose at 
Gss = 7.5, 9.5, 11.5, 12.5 mmol/L.  Clinical Studies: Circles: 
Gss = 7-8 mmol/L studies, Triangles: Gss = 9-10 mmol/L, 
Squares: Gss = 10-11 mmol/L, and the X is 12-13 mmol/L.  
Figures 5-8 show the waterfall plot results for the ND1 and 
ND2 models. The ND2 figures are for the values sorted for 
best FNZ results. The results of Figures 5-8 are significantly 
improved versus the MM results, as also seen in Table 2. 
This difference is largely due to the MM model’s linear 
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removal of glucose as a function of insulin (at a given 
glucose level), which prevent it from capturing clinical values 
above (relatively) very low insulin values. Hence, the 
saturation that is clearly evident in the clinical data cannot be 
captured by the MM dynamics, resulting in very large error 
values over the entire clinical data set.  
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Fig. 5: ND1 waterfall with data as defined in Figure 3. 
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Fig. 6: ND1 waterfall with data as defined in Figure 4. 
0 50 100 150
-0.4
-0.35
-0.3
-0.25
-0.2
-0.15
-0.1
-0.05
0
0.05
0.1
E
n
d
o
g
e
n
o
u
s
 B
a
la
n
c
e
 (
m
m
o
l/
L
/m
in
)
Insulin (mU/L)  
Fig. 7: ND2 waterfall with data as defined in Figure 3. 
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Fig.8: ND2 waterfall with data as defined in Figure 4. 
However, the ND models also fail to fully capture some 
clinical values. However, Figures 5 and 7 in particular show 
that from 30-100 mU/L on the insulin axis both models have 
difficulty capturing some of the clinical data points. 
Figures 9-10 show the RM model waterfalls. These plots 
more accurately fit the central portion of the clinical data, as 
expected due to the direct fitting of the model to this data. A 
salient difference is provided by the highly non-linear 
saturation curve of Equation (7), allowing the tighter 
distribution of constant glucose lines seen in these figures. 
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Fig.9: RM waterfall with data as defined in Figure 3. 
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Fig.10: RM waterfall with data as defined in Figure 4. 
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From the ND to RM models the difference in fit and 
behaviour are due primarily to two factors: 
1. A highly non-linear insulin effect saturation curve fit to 
the clinical data (Equation (7)) 
2. A separate saturated glucose loss in the periphery in 
Equation (5), along with independent saturation of 
glucose and insulin in Equations (6)-(7). 
The first difference appears in the insulin-endogenous 
balance plane and is illustrated in Figure 11. The RM model 
insulin saturation curve (scaled) is much sharper than the 
Michaelis-Menten saturation of the ND models. Different 
Michaelis-Menten constants thus fit the clinical data better at 
different insulin levels, but none work well over the entire 
range used here. In this case, 2-3 Michaelis-Menten constants 
work well in different ranges, where the RM fitted to the 
clinical data works over all ranges for this data. 
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Fig 11: Comparison of insulin saturation curves 
The sharper, highly non-linear saturation curve also results in 
the closer lines of constant glucose in Figures 9-10. The 
softer Michaelis-Menten term only offers the wider glucose 
curves in Figures 5-8. Thus, the ND model provides a lesser 
fit to this clinical data, which is more sharply saturated, as 
seen in all of Figures 3-10. Note that while the ND2 model is 
tighter with its second saturation, it is still not sharp enough 
to capture all the clinical data shown. This result thus 
suggests that there is a different saturation dynamic 
physiologically than is captured (fully) by Michaelis-Menten 
terms, at least over this range of clinical studies. 
Interestingly, the ND and RM model have qualitatively very 
similar errors. Thus, comparing Figures 5-7 to Figures 9-10, 
greater similarity might have been expected. This result 
shows how this PD surface approach can clearly delineate 
model differences more than point-wise error values. More 
specifically, it shows dual Michaelis-Menten saturations 
provide a better fit to otherwise variable clinical glycaemic 
clamp data than a single saturation, but that the shape of these 
saturation curves may not be ideal, at least in this case.  
However, the MM model is distinctly different, trying to 
adapt to its lack of dynamics by a lower SI value at the lower 
limit, matching reported under prediction when used in clamp 
studies. Importantly, the similar SI value for ND1 results in 
much smaller errors and is due to a trade off between SI and 
αG2. The MM model SI must be lowered by 10x to get RMS 
errors less than 0.5 or close to ND1 results, showing the 
reported under prediction of SI outside a physiological range 
for this model. These results also show how this PD surface 
analysis can clearly differentiate models.  
For further illustration, Figures 12-14 show the 3D PD 
surfaces for the RM, ND1 and ND2 models. They clearly 
show the flattening effect of the individual saturation 
dynamics, as well as the sharper saturation from Equation (7). 
However, qualitatively the fit to clinical data appears similar.  
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Figure 12: RM 3D surface, dots are clinical studies 
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Figure 13: ND1 3D surface, dots are clinical studies 
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Figure 14: ND2 3D surface, dots are clinical studies 
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In clinical situations, the ND models have shown very good 
predictive accuracy to within measurement error over 92% of 
the time, validating them for their clinical use in critical care 
(e.g. Wong et al, 2006; Hann et al, 2005). The RM model has 
less clinical validation, but 1-2 hour prediction accuracy 
using the same data (unpublished) yield essentially equivalent 
results to the ND model. Hence, both models, despite 
differences in the surfaces and dynamics in this analysis, are 
clinically effective for glycaemic management. 
Thus, the primary differences revolve around the shape of the 
saturation curve for insulin and the multiple glucose-insulin 
saturation dynamics. It is clear from this data that the sharper 
saturation of Equation (7) is potentially more physiological 
and should be validated with larger data sets. The separate 
saturations could also be incorporated into the ND model of 
Equation (1) and examined for improved predictive power. 
However, the current predictive accuracy of the ND and RM 
models is within measurement error over 90% of the time, so 
it may be difficult to further differentiate these models. 
This situation does not hold true for the Minimal Model 
(MM). This model is clearly deficient outside of low insulin 
and glucose values in Figures 4-5. The 3D surface of Figure 
15 with a z-axis 3x larger than Figures 12-14 clearly shows 
this result. The lack of well known physiological saturations 
and effects is clearly evident here, as in Table 2. 
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Figure 15: MM 3D surface, dots are clinical studies. 
4. CONCLUSIONS 
A new PD surface oriented approach to model validation has 
been presented for metabolic systems models. Two non-
linear, physiologically representative dynamic models (ND) a 
receptor-based (RM) model and the well-known Minimal 
Model (MM) were examined. The ND and RM models 
provide similar dynamics with salient differences due to the 
exact method of adding physiological saturation dynamics. In 
contrast, the MM is not physiologically representative 
enough to provide a 3D surface that captures the clinical data 
outside low insulin and glucose ranges, illustrating the 
difficulty in using this model for predictive glycaemic 
control. The reported under-prediction of insulin sensitivity 
by the MM is clearly evident. Comparing ND1 and ND2 
shows the need for two saturation terms in the ND1 model 
due to trade offs between insulin sensitivity and the second 
saturation term. The RM model would benefit from 
validation on additional data in future work. 
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